<a href="https://laohu8.com/S/SYRE">Spyre Therapeutics</a> Appoints Kate Tansey Chevlen as Chief Commercial Officer
Spyre Therapeutics Inc. has appointed Kate Tansey Chevlen as Chief Commercial Officer. She joins the company from Amgen, where she served as VP, Global Marketing Head for Immunology and Inflammation.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spyre Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9622959-en) on January 12, 2026, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments